US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

169.89

+11.427.21%

Pre-market: 170.000.1100+0.06%04:08 EDT

Volume:830.36K

Turnover:135.68M

Market Cap:547.81M

PE:- -

High:171.45

Open:157.00

Low:156.80

Close:158.47

52wk High:198.18

52wk Low:32.55

Shares:3.22M

Float Shares:3.22M

Volume Ratio:0.99

T/O Rate:25.75%

Dividend:1.34

Dividend Rate:0.79%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Health Care Roundup: Market Talk

Press Release: Residential Home Health Expands Eastern Pennsylvania Footprint with Acquisition of Covenant Home Health

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Myomo (MYO) and Hims & Hers Health (HIMS)

Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Codexis (CDXS) and Diamedica Therapeutics (DMAC)

A Look At Alignment Healthcare (ALHC) Valuation After The Recent 13.2 Million Share Secondary Offering

Simply Wall St.

Acadia Healthcare (ACHC) Is Up 9.3% After Massive Goodwill Impairment And Cautious 2026 Outlook

Simply Wall St.

Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Incyte (INCY)

Sector Update: Health Care Stocks Decline Premarket Monday

MT Newswires Live

This biotech's stock is soaring after a 'polarizing' FDA official is stepping down

FDA Vaccine Chief to Depart, Spotlight on Moderna

Bernie Sanders, Robert Reich And Ramit Sethi Question Billions Spent On Attacking Iran. 'People Do Not Want This. They Want Healthcare'

Analysts’ Top Healthcare Picks: IDEAYA Biosciences (IDYA), Lantheus (LNTH)

Analysts Are Bullish on Top Healthcare Stocks: Dianthus Therapeutics (DNTH), Lantheus (LNTH)

First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft-Tissue Diagnostics

Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Xenon’s Azetukalner Hits Phase 3 Mark in Focal Onset Seizures, Paving Way for FDA Filing

Trevi Therapeutics completes End-of-Phase 2 meeting with FDA

ImmunityBio resubmits sBLA to FDA for Anktiva plus BCG

Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough

Press Release: Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LABU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":169.89,"timestamp":1773086400000,"preClose":158.47,"halted":0,"volume":830361,"hourTrading":{"tag":"盘前","latestPrice":170,"preClose":169.89,"latestTime":"04:08 EDT","volume":6,"amount":1020,"timestamp":1773130116060,"change":0.11,"changeRate":0.000647,"amplitude":0},"delay":0,"changeRate":0.07206411308134024,"floatShares":3224486,"shares":3224486,"eps":0,"marketStatus":"Pre-Mkt","change":11.42,"latestTime":"03-10 05:18:27 EDT","open":157,"high":171.45,"low":156.8,"amount":135676536.66504,"amplitude":0.092447,"askPrice":171.6,"askSize":200,"bidPrice":163,"bidSize":14,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773149400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":169.89,"sharesOutstanding":3074486,"nav":158.249,"aum":510272375.11,"dividendRate":0.0079,"bidAskSpread":0.002103,"preHourTrading":{"tag":"盘前","latestPrice":170,"preClose":169.89,"latestTime":"04:08 EDT","volume":6,"amount":1020,"timestamp":1773130116060,"change":0.11,"changeRate":0.000647,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":167.7,"preClose":169.89,"latestTime":"19:59 EDT","volume":7391,"amount":1243699.2343,"timestamp":1773100771606,"change":-2.19,"changeRate":-0.012891,"amplitude":0.012891},"volumeRatio":0.9857082212472844,"impliedVol":1.0549,"impliedVolPercentile":0.896},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":3224486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.9857082212472844,"shares":3224486,"dividePrice":1.3421,"high":171.45,"amplitude":0.092447,"preClose":158.47,"low":156.8,"week52Low":32.55,"pbRate":"--","week52High":198.18,"institutionHeld":0,"latestPrice":169.89,"committee":-0.869159,"eps":0,"divideRate":0.0079,"volume":830361,"delay":0,"ttmEps":0,"open":157,"prevYearClose":159.39,"prevWeekClose":158.47,"prevMonthClose":172.7,"prevQuarterClose":159.39,"fiveDayClose":169.5,"twentyDayClose":166.47,"sixtyDayClose":157.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618678498","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2618678498","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618678498?lang=en_us&edition=fundamental","pubTime":"2026-03-10 00:20","pubTimestamp":1773073200,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0634 ET - Lonza's valuation of its capsule business looks \"modestly disappointing,\" RBC Capital Markets' Charles Weston writes in a note to clients. The Swiss healthcare-business manufacturer said late Friday that it will offload a majority stake in its capsule and health-ingredient division to investment firm Lone Star Funds in a deal that values the business at 2.3 billion Swiss francs. That looks a little under what analysts and investors might have expected, Weston says. \"This could be somewhat offset by positive sentiment around the buyback and future optionality for greater proceeds in the future and M&A deployment. RBC has an out","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","BK4585","XBI","XLV","BK4581"],"gpt_icon":0},{"id":"2618167862","title":"Press Release: Residential Home Health Expands Eastern Pennsylvania Footprint with Acquisition of Covenant Home Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2618167862","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618167862?lang=en_us&edition=fundamental","pubTime":"2026-03-10 00:13","pubTimestamp":1773072780,"startTime":"0","endTime":"0","summary":"\"Covenant's strong local relationships and skilled clinical teams strengthen our foundation in southeastern Pennsylvania,\" said Dee Grein, CEO, Graham Healthcare Group. \"By combining our resources and expertise, we are positioned to expand our services across the region, bringing high-quality nursing and therapy services to more patients while preserving the personalized care both organizations are known for.\". As the healthcare landscape continues to evolve, Residential remains focused on delivering measurable outcomes, strengthening community partnerships, and ensuring patients receive exceptional care from clinicians they know and trust.  Residential plans to retain Covenant's employees and is committed to ensuring a seamless transition for patients, families, referral partners, and staff. Current patients will experience no interruption in services.Graham Healthcare Group  is a subsidiary of Graham Holdings Company . GHG companies include Residential Home Health, Residential Hospic","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4204","GHG","BK4142","BK4581","EML","BK4211","BK4195","GHC","XLV","BK4585","XBI","BK4588","LABU","BK4161","HBCP"],"gpt_icon":0},{"id":"2618627402","title":"Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Myomo (MYO) and Hims & Hers Health (HIMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618627402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618627402?lang=en_us&edition=fundamental","pubTime":"2026-03-09 22:50","pubTimestamp":1773067811,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dianthus Therapeutics (DNTH – Research Report), My...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dianthus-therapeutics-dnth-myomo-myo-and-hims-hers-health-hims-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dianthus-therapeutics-dnth-myomo-myo-and-hims-hers-health-hims-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","HIMZ","BK4137","LABU","LU0128526141.USD","BK4588","BK4581","HIMS","HIYY","BK4196","HMYY","HIMY","LU0029874061.USD","BK4082","DNTH","MYO","XBI","BK4139"],"gpt_icon":0},{"id":"2618762234","title":"Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Codexis (CDXS) and Diamedica Therapeutics (DMAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618762234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618762234?lang=en_us&edition=fundamental","pubTime":"2026-03-09 22:20","pubTimestamp":1773066033,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Savara (SVRA – Research Report), Codexis (CDXS – Res...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-savara-svra-codexis-cdxs-and-diamedica-therapeutics-dmac-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-savara-svra-codexis-cdxs-and-diamedica-therapeutics-dmac-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4137","LABU","LU0128526141.USD","BK4588","BK4581","DMAC","SVRA","XLV","LU0029874061.USD","BK4121","XBI","HCSG","CDXS","BK4139"],"gpt_icon":0},{"id":"2618627606","title":"A Look At Alignment Healthcare (ALHC) Valuation After The Recent 13.2 Million Share Secondary Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2618627606","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618627606?lang=en_us&edition=fundamental","pubTime":"2026-03-09 22:20","pubTimestamp":1773066015,"startTime":"0","endTime":"0","summary":"Alignment Healthcare (ALHC) is back in focus after an existing stockholder sold about 13.2 million shares in a secondary offering, increasing public float and liquidity without adding new capital to the company.\nSee our latest analysis for Alignment Healthcare.\nThe secondary sale and recent shelf registration have come alongside mixed price action, with the 1 month share price return of 15.22% and year to date share price return of 8.8% contrasting with a 1 year total shareholder return of...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6034000-choice2-main-header/1585187286151","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6034000-choice2-main-header/1585187286151"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-alhc/alignment-healthcare/news/a-look-at-alignment-healthcare-alhc-valuation-after-the-rece","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-alhc/alignment-healthcare/news/a-look-at-alignment-healthcare-alhc-valuation-after-the-rece","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4154","BK4539","BK4585","XBI","ALHC","BK4581","LABU","XLV","BK4588"],"gpt_icon":0},{"id":"2618067622","title":"Acadia Healthcare (ACHC) Is Up 9.3% After Massive Goodwill Impairment And Cautious 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2618067622","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618067622?lang=en_us&edition=fundamental","pubTime":"2026-03-09 22:19","pubTimestamp":1773065949,"startTime":"0","endTime":"0","summary":"In February 2026, Acadia Healthcare Company reported fourth-quarter 2025 revenue of US$821.46 million but recorded a net loss of US$1.18 billion, largely driven by a US$996.20 million non-cash goodwill impairment, even as full-year 2025 sales reached US$3.31 billion.\nDespite the large impairment-driven loss, management issued 2026 revenue guidance of US$3.37 billion to US$3.45 billion and flagged a modest 0%–1% same-facility volume range, highlighting how policy changes in New York Medicaid...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice2-main-header/1585186569462","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice2-main-header/1585186569462"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-achc/acadia-healthcare/news/acadia-healthcare-achc-is-up-93-after-massive-goodwill-impai","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-achc/acadia-healthcare/news/acadia-healthcare-achc-is-up-93-after-massive-goodwill-impai","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4581","LABU","XLV","BK4585","BK4185","BK4588","ACHC","XBI"],"gpt_icon":0},{"id":"2618621895","title":"Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Incyte (INCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618621895","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618621895?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:21","pubTimestamp":1773062464,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Revolution Medicines (RVMD – Research Report), Incyt...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-revolution-medicines-rvmd-incyte-incy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-revolution-medicines-rvmd-incyte-incy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4137","INCY","LABU","LU0128526141.USD","BK4588","BK4581","BK4532","XLV","LU0029874061.USD","RVMD","XBI","HCSG","BK4550","BK4139"],"gpt_icon":0},{"id":"2618762902","title":"Sector Update: Health Care Stocks Decline Premarket Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2618762902","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618762902?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:20","pubTimestamp":1773062412,"startTime":"0","endTime":"0","summary":"Health care stocks were declining premarket Monday, with the State Street Health Care Select Sector SPDR ETF  0.9% lower and the iShares Biotechnology ETF  down 1.1%.Novo Nordisk  planned to sell its weight loss drugs on Hims & Hers Health's  platform, Bloomberg reported, citing an unnamed person familiar with the matter. Shares of Hims & Hers Health were up more than 46% pre-bell.Hutchmed  stock was down nearly 4% after the company said it has initiated the withdrawal and recall of Tazverik in mainland China, Hong Kong and Macau after Ipsen decided to voluntarily withdraw the drug from the US market.Xenon Pharmaceuticals  shares were up more than 43% after the company said topline results show its phase 3 X-TOLE2 study of azetukalner met its primary endpoint of median percent change in monthly focal onset seizures frequency in both dose groups in 12 weeks compared to placebo.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","IE00BKVL7J92.USD","NVOX","BK4196","XBI","LU1093756168.USD","BK4139","LABU","BK4532","LU0154236417.USD","HIMZ","BK4581","BK4531","BK4599","LU1093756325.SGD","BK4007","BK4588","BK7104","HIMY","XLV","NVOH","IBB","HIYY","IE00BZ1G4Q59.USD","HMYY"],"gpt_icon":1},{"id":"2618462921","title":"This biotech's stock is soaring after a 'polarizing' FDA official is stepping down","url":"https://stock-news.laohu8.com/highlight/detail?id=2618462921","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618462921?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:18","pubTimestamp":1773062280,"startTime":"0","endTime":"0","summary":"Shares of UniQure, which is developing a gene therapy for Huntington's disease, are rallying. Vinay Prasad, an official for the Food and Drug Administration, is reportedly stepping down.UniQure's stock  was up 38% in premarket trading on Monday. Late Friday, the FDA told the Wall Street Journal that Vinay Prasad plans to leave the agency next month. He is the director of the FDA's Center for Biologics Evaluation and Research, which oversees vaccines and rare-disease drugs.Prasad had reportedly been involved in the decision to request a new trial for uniQure's experimental gene therapy for Huntington's disease. UniQure's stock plunged on that request, falling 33% in a single day, and the action led to a broader discussion about the expertise of current FDA leadership and how rare-disease-focused biotechs have struggled to advance therapies under those leaders.\"Prasad was a polarizing figure as exemplified by his involvement in rare-disease drug regulatory reversals, an initial refusal  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4563","LU0109394709.USD","BK4568","RGNX","XBI","BK4548","MRNY","BK4139","BK4534","BK4532","BK4581","BK4501","MRNX","BK4533","BK4505","BK4585","LABU","BK4551","QURE","BK4588","LU0320765992.SGD"],"gpt_icon":1},{"id":"1169021246","title":"FDA Vaccine Chief to Depart, Spotlight on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=1169021246","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169021246?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:15","pubTimestamp":1773062115,"startTime":"0","endTime":"0","summary":"The departure of the FDA's Vinay Prasad following controversies in reviews, including Moderna's flu vaccine and a Huntington's disease therapy, has drawn attention from stakeholders of Moderna and uniQure.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","159646","BK4588","LABU"],"gpt_icon":0},{"id":"2618621884","title":"Bernie Sanders, Robert Reich And Ramit Sethi Question Billions Spent On Attacking Iran. 'People Do Not Want This. They Want Healthcare'","url":"https://stock-news.laohu8.com/highlight/detail?id=2618621884","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618621884?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:07","pubTimestamp":1773061620,"startTime":"0","endTime":"0","summary":"Criticism has come from across politics, academia and the business world. Sen. Bernie Sanders , for example, warned that the U.S. is already committing massive sums to defense while the Trump administration pushes for even more funding tied to the conflict.On Wednesday, Sanders wrote on X that the Pentagon already received nearly $1 trillion and that additional requests were being made as the conflict unfolds.“We just gave the Pentagon nearly $1 trillion,” Sanders wrote. “Then Trump asked for $500 billion more. Now he wants even more money for a war he started in Iran without congressional approval.”“The answer is NO,” he added. “We need to invest in the American people, not more endless wars.”“Hey why haven’t I heard a single Republican asking ‘HOW ARE WE GOING TO PAY FOR IT?’ referring to the billions we’re spending attacking Iran when they constantly ask that when we try to institute universal healthcare & social services for the poor,” Sethi wrote on X on Thursday.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/09/Tehran-Fuel-Depots-Targeted.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/09/Tehran-Fuel-Depots-Targeted.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/topics/26/03/51126144/bernie-sanders-robert-reich-and-ramit-sethi-question-billions-spent-on-attacking-iran-people-do-not-want-this-they-want-healthcare","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/topics/26/03/51126144/bernie-sanders-robert-reich-and-ramit-sethi-question-billions-spent-on-attacking-iran-people-do-not-want-this-they-want-healthcare","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4588","BK4137","LU0029874061.USD","BK4585","HCSG","XLV","LU0128526141.USD","XBI","LABU","BK4581"],"gpt_icon":0},{"id":"2618629565","title":"Analysts’ Top Healthcare Picks: IDEAYA Biosciences (IDYA), Lantheus (LNTH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618629565","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618629565?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:01","pubTimestamp":1773061273,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on IDEAYA Biosciences (IDYA – Research Report) and Lant...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-ideaya-biosciences-idya-lantheus-lnth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-ideaya-biosciences-idya-lantheus-lnth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4581","LABU","HCSG","BK4198","XLV","IDYA","BK4137","BK4585","LU0128526141.USD","LNTH","BK4588","XBI","BK4139"],"gpt_icon":0},{"id":"2618302629","title":"Analysts Are Bullish on Top Healthcare Stocks: Dianthus Therapeutics (DNTH), Lantheus (LNTH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618302629","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618302629?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:50","pubTimestamp":1773060650,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dianthus Therapeutics (DNTH – Research Report), Lant...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-dianthus-therapeutics-dnth-lantheus-lnth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-dianthus-therapeutics-dnth-lantheus-lnth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4198","BK4588","BLSG","BK4137","LABU","LNTH","LU0029874061.USD","LU0128526141.USD","XBI","BK4585","BK4581","BK4139","BLSX","BK4112","DNTH"],"gpt_icon":0},{"id":"2618626606","title":"First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft-Tissue Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2618626606","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618626606?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:30","pubTimestamp":1773059400,"startTime":"0","endTime":"0","summary":"Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251807/0/en/First-ever-Dental-Dedicated-MRI-Validated-in-Clinical-Trial-and-Cleared-by-FDA-for-Advanced-Soft-Tissue-Diagnostics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEIS","BK4585","LU0757428866.USD","IE00B7SZL793.SGD","LU1815336091.USD","BK4157","BK4097","IE00B66KJ199.SGD","LABU","IE00B19Z4B17.USD","BK4588","IE0031619046.USD","ADEA"],"gpt_icon":0},{"id":"2618962549","title":"Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2618962549","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618962549?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:05","pubTimestamp":1773057900,"startTime":"0","endTime":"0","summary":"Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251796/33816/en/Sangamo-Therapeutics-Advances-Rolling-Submission-of-BLA-to-U-S-FDA-for-ST-920-in-Fabry-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","BK4585","BK4139","LABU","LENZ","BK4588"],"gpt_icon":0},{"id":"2618359625","title":"Xenon’s Azetukalner Hits Phase 3 Mark in Focal Onset Seizures, Paving Way for FDA Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618359625","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618359625?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:58","pubTimestamp":1773057533,"startTime":"0","endTime":"0","summary":"Xenon ( ($XENE) ) just unveiled an update. Xenon Pharmaceuticals reported positive topline results from its Phase 3 X-TOLE2 trial of azetukalner in...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xenons-azetukalner-hits-phase-3-mark-in-focal-onset-seizures-paving-way-for-fda-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xenons-azetukalner-hits-phase-3-mark-in-focal-onset-seizures-paving-way-for-fda-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","LABU"],"gpt_icon":0},{"id":"2618623620","title":"Trevi Therapeutics completes End-of-Phase 2 meeting with FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623620","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618623620?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:41","pubTimestamp":1773056468,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics (TRVI) announced the results of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration, FDA. At the meeting, the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/trevi-therapeutics-completes-end-of-phase-2-meeting-with-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/trevi-therapeutics-completes-end-of-phase-2-meeting-with-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","TRVI","LABU","LENZ","BK4585","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2618623935","title":"ImmunityBio resubmits sBLA to FDA for Anktiva plus BCG","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623935","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618623935?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:35","pubTimestamp":1773056138,"startTime":"0","endTime":"0","summary":"ImmunityBio (IBRX) announced that the U.S. FDA has acknowledged receipt of its supplemental Biologics License Application for Anktiva plus Bacillus...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunitybio-resubmits-sbla-to-fda-for-anktiva-plus-bcg-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunitybio-resubmits-sbla-to-fda-for-anktiva-plus-bcg-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","IBRX","BCG","BK4139","BK4135","BK4588"],"gpt_icon":0},{"id":"2618238886","title":"Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough","url":"https://stock-news.laohu8.com/highlight/detail?id=2618238886","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618238886?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:30","pubTimestamp":1773055800,"startTime":"0","endTime":"0","summary":"The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251724/0/en/Trevi-Therapeutics-Announces-Completion-of-End-of-Phase-2-Meeting-with-the-FDA-Gaining-Alignment-for-Its-Development-Program-for-Idiopathic-Pulmonary-Fibrosis-Related-Chronic-Cough.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABU","LENZ","RCC","BK4588","BK4539","BK4585","BK4007"],"gpt_icon":0},{"id":"2618064076","title":"Press Release: Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2618064076","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618064076?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:05","pubTimestamp":1773054300,"startTime":"0","endTime":"0","summary":"Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B  on Track for the Fourth Quarter of 2026. Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company's Commercial Capabilities in Preparation for a Potential Launch of TA-ERT. Secured up to $50 Million in Growth Capital from Avenue Capital Group. Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate updates.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052756011.USD","LABU","SG9999001440.SGD","LU0072461881.USD","LU0128525689.USD","BK4175","LU0792757196.USD","BK4585","BK4139","LU1571399168.USD","PA3.SI","LU0310799852.SGD","LU1880398554.USD","LU1880398471.USD","LU0310800965.SGD","BK4604","LU0211327993.USD","LU1267930490.SGD","LU0006061336.USD","CAH","LU0211328371.USD","LU1267930813.SGD","TM","BK4555","LU0889566641.SGD","LU0162691827.USD","LU1267930227.SGD","LU0154236417.USD","03160","BK4588","SPRB","BK4099","BK6045","BK6512"],"gpt_icon":0}],"pageSize":20,"totalPage":22,"pageCount":2,"totalSize":435,"code":"91000000","status":"200"}]}}